Skip to main content
SpringerLink
Log in
Book cover

Kompendium Internistische Onkologie pp 3787–3937Cite as

Kolorektales Karzinom

  • Chapter

Zusammenfassung

Häufigkeit: Karzinome des Kolons und des Rektums sind in Europa die häufigste Krebserkrankung, in den USA die vierthäufigste und in Deutschland die zweithäufigste Krebserkrankung nach dem Prostatakarzinom beim Mann bzw. Mammakarzinom der Frau. Nach dem Bronchialkarzinom steht das Kolon-/Rektumkarzinom in Europa an der zweiten Stelle der Mortalitätsskala nach dem Lungenkarzinom mit 138 400 Toten jährlich (EU: 2000, CancerStats 2005).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Aarnio S, Mecklin JP, Aaltonen S et al (1995) Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64(6):430–433

    Article  PubMed  CAS  Google Scholar 

  • Abdel-Rahman WM, Peltomäki P (2004) Molecular basis and diagnostics of hereditary colorectal cancers. Ann Med 36:379–388

    Article  PubMed  CAS  Google Scholar 

  • Adam R, Delvart V, Pascal G et al (2004). Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 240(4):644–657

    PubMed  Google Scholar 

  • Ahmed FE (2003) Colon cancer: Prevalence, Screening, Gene Expression and Mutation, and Risk Factors and Assessment. J Environ Sci Health B, Vol C21:65–131

    CAS  Google Scholar 

  • Alberts SR, Donohue JH, Mahoney MR et al (2003) Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer limited to the liver: A North Central Cancer Treatment (NCCTG) phase II study. Proc Am Soc Clin Oncol 22:263a, abstr. 1053

    Google Scholar 

  • André T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351

    Article  PubMed  Google Scholar 

  • Arkenau H, Schmoll HJ, Kubicka S et al (2005) Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. Proc. ASCO; Abstr. 3507

    Google Scholar 

  • Arnold D, Schmoll HJ (2005) (Neo-)adjuvant treatments in colorectal cancer. Ann Oncol 16 (Suppl):2:ii133–ii140

    Article  PubMed  Google Scholar 

  • Beets-Tan RG, Beets GL, Vliegen JF (2001) Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 17, 357:497–504

    Article  Google Scholar 

  • Benson AB, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419

    Article  PubMed  Google Scholar 

  • Bismuth H, Adam R, Levi F et al (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–520

    Article  PubMed  CAS  Google Scholar 

  • Blanke CD, Benson AB, Dragovich T et al (2002) A phase II trial of celecoxib (CX), irinotecan and leucovorin in patients with unresectable or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 21:127a, abstr. 505

    Google Scholar 

  • Bosset JF, Calais G, Mineur L et al (2005) Preoperative radiation (Preop RT) in rectal cancer: effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial. Proc. ASCO; Abstr. 3505

    Google Scholar 

  • Bromer MQ, Weinberg DS (2005) Screening for colorectal cancer — now and the near future. Semin Oncol 32:3–10

    Article  PubMed  Google Scholar 

  • Brown G, Daniels IR (2005) Preoperative staging of rectal cancer: the MERCURY research project. Recent Results Cancer Res 165:58–74

    Article  PubMed  CAS  Google Scholar 

  • Brown G, Richards CJ, Bourne MW et al (2003) Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology 227(2):371–377

    Article  PubMed  Google Scholar 

  • Brown JR, DuBois RN (2005) Cox-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23(12):2840–2854

    Article  PubMed  CAS  Google Scholar 

  • Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2004) Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionnally fractionated radiochemotherapy. Radiother Oncol 2004: http://www.sciencedirect.com/science/journal/01678140

  • Cassidy J, Tabernero J, Twelves C et al (2004) XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084–2091

    Article  PubMed  CAS  Google Scholar 

  • Cassidy J, Twelves C, van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous fluorouracil/leucovorin. Ann Oncol 13:566–575

    Article  PubMed  CAS  Google Scholar 

  • Chung KY, Shia J, Kemeny NE et al (2005). Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803–1810

    Article  PubMed  CAS  Google Scholar 

  • Coleman MP, Gatta G, Verdecchia A et al (2003) and the EUROCAREWorking Group (2003) EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 14(S5):128–149

    Article  Google Scholar 

  • Cunningham D, Humblet Y, Siena S et al (2003) Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 22:252, abstr. 1012

    Google Scholar 

  • Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and Cetuximab plus Irinotecan in Irinotecan-refractory metastatic colorectal cancer. N Engl J Med 35:4:337–345

    Article  Google Scholar 

  • De Gramont A, Boni C, Navarro M et al (2005) Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc. ASCO; Abstr. 3501

    Google Scholar 

  • De Gramont A, Bosset F, Milan C et al (1997) Randomized trial comparing low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup Study. J Clin Oncol 15:808–15

    PubMed  Google Scholar 

  • De Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  • de la Chapelle A (2004) Genetic predisposition to colorectal cancer. Nature Reviews Cancer 4:769–780

    Article  PubMed  Google Scholar 

  • Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047

    Article  PubMed  CAS  Google Scholar 

  • Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12(1):19–23

    Article  PubMed  CAS  Google Scholar 

  • Eickhoff A, Riemann F (2005) Prophylaxe und Früherkennung In: Schölmerich J, Schmiegel W (Hrsg.): Leitfaden kolorektales Karzinom. 2. Auflage, Uni-Med: 36–45

    Google Scholar 

  • Figueredo A, Charette ML, Maroun J et al (2004) Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidencebased care’s gastrointestinal cancer disease site group. J Clin Oncol 22:3395–3407

    Article  PubMed  Google Scholar 

  • Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16(8):1311–1319

    Article  PubMed  CAS  Google Scholar 

  • Fürst A, Jauch K.W, Kleespiess A (2005) Stadieneinteilung kolorektaler Karzinome In: Schölmerich J, Schmiegel W (Hrsg.): Leitfaden kolorektales Karzinom. 2. Auflage, Uni-Med: 74–87

    Google Scholar 

  • Gatta G, Ciccolallo L, Capocaccia R et al (2003) and the EUROCAREWorking Group (2003) Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology. Eur J Cancer 39:2214–2222

    Article  PubMed  CAS  Google Scholar 

  • Gerard J, Bonnetain F, Conroy T et al (2005) Preoperative (preop) radiotherapy (RT) + 5 FU/folinic acid (FA) in T3-4 rectal cancers: results of the FFCD 9203 randomized trial. Proc. ASCO; Abstr. 3504

    Google Scholar 

  • Giacchetti S, Perpoint B, Zidani R, et al.: Phase I/II multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136–147

    PubMed  CAS  Google Scholar 

  • Giantonio BJ, Catalano PJ, Meropol NJ et al (2005) High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. ASCO; Abstr. 2

    Google Scholar 

  • Gill S, Loprinzi CL, Sargent DJ et al (2004) Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 22:1797–1806

    Article  PubMed  CAS  Google Scholar 

  • Glynne-Jones R (2005) Preoperative chemoradiation in rectal cancer: why we need a common language. Onkologie 28(5):237–240

    Article  PubMed  Google Scholar 

  • Goldberg R, Morton R, Sargent D et al (2003) N9741: oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an intergroup study. Proc Am Soc Clin Oncol 22:252, abstr. 1009

    Google Scholar 

  • Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30

    Article  PubMed  CAS  Google Scholar 

  • Gray RG, Barnwell J, Hills R et al (2004) QUASAR: A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients. Proc. ASCO

    Google Scholar 

  • Grem JL (2005) Intratumoral Molecular or Genetic Markers as Predictors of Clinical Outcome with chemotherapy in Colorectal Cancer. Semin Oncol 32:120–127

    Article  PubMed  CAS  Google Scholar 

  • Grothey A, Jordan K, Kellner O et al (2003) Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC) Proc Am Soc Clin Oncol 23:255, abstr. 1022

    Google Scholar 

  • Grothey A, Sargent D, Goldberg R M, Schmoll H-J (2004) Survival of patients with advanced colorectal cancer improves with the availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the course of treatment. J Clin Oncol 22:1209–1214

    Article  PubMed  CAS  Google Scholar 

  • Harba AE, Jordan K, Kegel T et al (2003) Capecitabine/mitomycin C as salvage therapy in oxaliplatin and CPT-11 refractory colorectal cancer. Proc Am Soc Clin Oncol 22:259, abstr. 3246

    Google Scholar 

  • Hartung G, Hofheinz RD, Dencausse Y et al (2005) Adjuvant therapy with edrecolomab versus observation in stage II colon cancer: A multicenter randomized phase III study. Onkologie 28:347

    Article  PubMed  CAS  Google Scholar 

  • Hoff PM, Ansari R, Batist G et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line therapy in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282–2292

    PubMed  CAS  Google Scholar 

  • Hofheinz RD, Gerstenberg-Helldorf B von, Wenz F et al (2005) Phase l trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 23:1350–1357

    Article  PubMed  CAS  Google Scholar 

  • Hofheinz RD, Hartmann JT, Willer A et al (2004) Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: Results of an extended multicenter phase I trial. Br J Cancer 91:834–838

    PubMed  CAS  Google Scholar 

  • Hofstädter F, Rummele P (2005) Epidemiologie des sporadischen kolorektalen Karzinoms und seiner Vorstufen — Inzidenz, Prävalenz, Risikofaktoren In: Schölmerich J, Schmiegel W (Hrsg.): Leitfaden kolorektales Karzinom. 2. Auflage, Uni-Med: 18–35

    Google Scholar 

  • Hohenberger W, Dürsch M (2005) Chirurgische Therapie des kolorektalen Karzinoms. In: Schölmerich J, Schmiegel W (Hrsg.): Leitfaden kolorektales Karzinom 2. Auflage, Uni-Med:108–123

    Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  • Ilyas M, Straub J, Tomlinson IPM et al (1999) Genetic pathways in colorectal and other cancers. Eur J Cancer 35:335–351

    Article  PubMed  CAS  Google Scholar 

  • Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65

    Article  PubMed  CAS  Google Scholar 

  • Kabbinavar FF, Hambleton J, Mass RD et al (2005) Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706–3712

    Article  PubMed  CAS  Google Scholar 

  • Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697–3705

    Article  PubMed  CAS  Google Scholar 

  • Kapiteijn E, Marijnen CAM, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for respectable rectal cancer. N Engl J Med 345:638–646

    Article  PubMed  CAS  Google Scholar 

  • Kerr D, Ten Bokkel Huinink W, Ferry D et al (2002) A phase l/ll study of CPT-11 in combinationwith capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 21:161a, abstr. 643

    Google Scholar 

  • Kluge S, Boeing H (2004) Beitrag der Ernährung zur Primärprävention in der Onkologie. Onkologe 10:139–147

    Article  Google Scholar 

  • Köhne CH, Cunningham D, Di CF et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 13(2):308–317

    Article  PubMed  Google Scholar 

  • Köhne CH, van Cutsem E, Wils J et al (2005) Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 22:4856–4865

    Article  Google Scholar 

  • Kullmann F (2005) Familiäre Formen des kolorektalen Karzinoms. Genetik, Klinik und Diagnostik In: Schölmerich J, Schmiegel W (Hrsg.): Leitfaden kolorektales Karzinom. 2. Auflage, Uni-Med: 46–59

    Google Scholar 

  • Lamberti C, Sauerbruch T (2005) Frühdiagnostik kolorektaler Tumoren. Internist 4:401–410

    Article  Google Scholar 

  • Lenz HJ, Mayer RJ, Gold PJ et al (2004) Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc. ASCO; Abstr. 3510

    Google Scholar 

  • Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:2038–2048

    Google Scholar 

  • Leung KL, Kwok SPY, Lam SCW (2004) Laparoscopic resection of rectosigmoid carcinoma: prospective randomised trial. Lancet 363(10):1187–1192

    Article  PubMed  Google Scholar 

  • Le Voyer, Sigurdson ER, Hanlon L et al (2003) Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912–2919

    Article  PubMed  Google Scholar 

  • Müller O (2003) Identification of colon cancer patients by molecular diagnosis. Dig Dis 21:315–319

    Article  PubMed  Google Scholar 

  • Mamounas E, Wieand S, Wolmark N et al (1999) Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, C-04) J Clin Oncol; 17:1349–1355

    PubMed  CAS  Google Scholar 

  • Marijnen C, Peeters K, Putter H et al (2005) Long-term results, toxicity and quality of life in the TME trial. Proc. ASCO GI Meeting 2005, Abstr. 166

    Google Scholar 

  • Mendelsohn J, Howley PM, Israel MA et al The Molecular Basis of Cancer. 2nd Ed, WB Saunders Company

    Google Scholar 

  • Messmann H (2005) Polypenmanagement In: Schölmerich J, Schmiegel W (Hrsg.): Leitfaden kolorektales Karzinom. 2. Auflage, Uni-Med: 60–73

    Google Scholar 

  • Meta-analysis group in cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308

    Google Scholar 

  • Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281

    Article  PubMed  CAS  Google Scholar 

  • Molatore S, Ranzani GN (2004) Genetics of colorectal polyps. Tech Coloprotocol 8:240–242

    Article  Google Scholar 

  • Nordic Gastrointestinal Tumor Adjuvant Therapy Group (1992) Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10(6):904–911

    Google Scholar 

  • O’Connell MJ, Martenson JA, Wieand HS et al (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. New Engl J Med 331:502–507

    Article  PubMed  Google Scholar 

  • O’Connell MJ, Wolmark N, Yothers G et al (2005) Durable improvement in diseasefree survival (DFS) and overall survival (OS) for stage II or III colon cancer treated with leucovorin-modulated fluorouracil (FL): 10-year follow-up of NSABP C-03. Proc. ASCO; Abstr. 3511

    Google Scholar 

  • Osborn N, Ahlquist DA (2005) Stool screening for colorectal cancer: Molecular approaches. Gastroenterology 128(1):192–206

    Article  PubMed  CAS  Google Scholar 

  • Patt YZ, Liebmann J, Diamondidis D et al (2004) Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial. Proc ASCO; Abstr. 3602

    Google Scholar 

  • Rao S, Cunningham D, Price T et al (2004) Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer 91, 839–843

    PubMed  CAS  Google Scholar 

  • Riethmüller G, Holz E, Schlimok G et al (1998) Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788–1794

    PubMed  Google Scholar 

  • Rödel C, Grabenbauer GG, Papadopoulos T et al (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 21:3098–3104

    Article  PubMed  Google Scholar 

  • Rödel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression grading following preoperative chemoradiotherapy for rectal cancer. J Clin Oncol (in press).

    Google Scholar 

  • Ross P, Normann A, Cunningham D et al (1997) A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol; 8:995–1001

    Article  PubMed  CAS  Google Scholar 

  • Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of Oxaliplatin and Fluorouracil-Leucovorin compared with either therapy alone in patients with progressive colorectal cancer after Irinotecan and Fluorouracil-Leucovorin: Interim Results of a phase III trial. J Clin Oncol 21(11); 2059–2069

    Article  PubMed  CAS  Google Scholar 

  • Rougier P, van Cutsem E, Bajetta E et al (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407–1412

    Article  PubMed  CAS  Google Scholar 

  • Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914

    Article  PubMed  CAS  Google Scholar 

  • Saltz LB, Lenz H, Hochster H et al (2005) Randomized phase II trial of cetuximab, bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc. ASCO; Abstr 3508

    Google Scholar 

  • Saltz LB, Meropol NJ sr, Needle MN et al (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208

    Article  PubMed  CAS  Google Scholar 

  • Sargent DJ, Niedzwicki D, O’Connell MJ et al (2001) Recommendations for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144–145

    Article  PubMed  CAS  Google Scholar 

  • Sargent DJ, Wieand S, Benedetti J et al (2004) Disease-free survival (DFS) vs. overall survival (OS) as a primary endpoint for adjuvant colon cancer studies: Individual patient data from 12,915 patients on 15 randomized trials. Proc ASCO; Abstr. 3502

    Google Scholar 

  • Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740

    Article  PubMed  CAS  Google Scholar 

  • Scheithauer W, Rosen H, Kornek GV et al (1993) Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 306:752–755

    Article  PubMed  CAS  Google Scholar 

  • Schmiegel W, Pox C, Adler G et al (2004) S3-Leitlinienkonferenz „Kolorektales Karzinom“. Z Gastroenterol 10(XLII): 1129–1177

    Google Scholar 

  • Schmoll HJ, Grothey A, Kroening H et al (2005) A phase III study comparing bolus 5-fluorouracil/folinic acid with weekly 24h-infusion of high-dose 5-fluorouracil/folinic acid plus oxaliplatin as first-line therapy in advanced colorectal cancer. J Clin Oncol (submitted).

    Google Scholar 

  • Schmoll HJ, Tabernero J, Nowacki M et al (2005) Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. Proc ASCO; Abstr. 3523

    Google Scholar 

  • Schuller J, Cassidy J, Dumont E (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297

    Article  PubMed  CAS  Google Scholar 

  • Seymour MT (2005) Fluorouracil, Oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): A 2135-patient randomized trial in advanced colorectal cancer (ACRC). ASCO; Abstr 3518

    Google Scholar 

  • Stahl M, Schweers K, Müller C et al (2005) Application of adjuvant chemotherapy in colorectal cancer — a survey in the region of Essen, Germany. Onkologie 28(1):7–10.

    Article  PubMed  CAS  Google Scholar 

  • Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987

    Article  Google Scholar 

  • Tan BR, McLeod HL (2005) Pharmacogenetic Influences on Treatment Response and Toxicity in Colorectal Cancer. Semin Oncol 32:113–119

    Article  PubMed  CAS  Google Scholar 

  • Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229–237

    Article  PubMed  CAS  Google Scholar 

  • Tuynman JB, Peppelenbosch MP, Richel DJ (2004) Cox-2 Inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Hematol Oncol 52:81–101

    Article  CAS  Google Scholar 

  • Twelves C (1999) UFT plus calcium folinate/irinotecan in colorectal cancer. Oncology (Huntingt) 13:51–54

    CAS  Google Scholar 

  • Twelves C, Wong A, Marek P et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 26:2696–2704

    Article  Google Scholar 

  • Van Cutsem E, Labianca R, Hossfeld D et al (2005) Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients. (PETACC 3). Proc ASCO Abstr. 8

    Google Scholar 

  • Van Cutsem E, Twelfes C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097–4106

    PubMed  Google Scholar 

  • van Triest B, Pinedo HM, Blaauwgeers JL et al (2000) Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 6:1063–1072

    PubMed  Google Scholar 

  • Vanhoefer U, Harstrick A, Köhne CH (1999) Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 17:907–913

    PubMed  CAS  Google Scholar 

  • Watanabe T, Wu TT, Catalano PJ et al (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344(16):1196–1206

    Article  PubMed  CAS  Google Scholar 

  • Wittekind C, Tannapfel A (2003) Regression grading of colorectal carcinoma after preoperative radiochemotherapy. An inventory. Pathologe 245(1):61–65

    Google Scholar 

  • Wolmark N, Rockette H Fisher B et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879–1887

    PubMed  CAS  Google Scholar 

  • Wolmark N, Wieand HS, Kuebler JP et al (2005) A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: Results of NSABP Protocol C-07. Proc. ASCO; Abstr. 3500

    Google Scholar 

  • Wong-Seok J, Chung DC (2005) Genetics of hereditary colorectal cancer. Semin Oncol 32:11–23

    Google Scholar 

Download references

Authors
  1. H. J. Schmoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Schwerpunkt Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle/Saale

    Hans-Joachim Schmoll (Direktor der Klinik und Poliklinik für Innere Medizin IV) (Direktor der Klinik und Poliklinik für Innere Medizin IV)

  2. Onkologie-Hämatologie-Gastroenterologie-Hepatologie-Infektiologie, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, 07740, Jena

    Klaus Höffken (Direktor der Klinik und Poliklinik für Innere Medizin II) (Direktor der Klinik und Poliklinik für Innere Medizin II)

  3. Schwerpunkt Onkologie und Hämatologie, Universitätsmedizin Berlin, Charité-Campus Mitte Schumannstraße 20/21, 10117, Berlin

    Kurt Possinger (Direktor der Medizinischen Klinik II) (Direktor der Medizinischen Klinik II)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Schmoll, H.J., Arnold, D. (2006). Kolorektales Karzinom. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-31303-6_212

Download citation

  • DOI: https://doi.org/10.1007/3-540-31303-6_212

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20657-6

  • Online ISBN: 978-3-540-31303-8

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation